Welcome to our dedicated page for Pfizer news (Ticker: PFE), a resource for investors and traders seeking the latest updates and insights on Pfizer stock.
Pfizer Inc. reports developments across its global biopharmaceutical business, including prescription medicines, vaccines, biosimilars, sterile injectables, and oncology therapies. Recurring news covers financial results and guidance, commercial portfolio changes within Biopharma, dividend declarations, capital allocation priorities, and product access initiatives for established medicines such as Eliquis.
Company updates also address clinical and regulatory activity across Pfizer's pipeline and marketed products. Recent themes include oncology data presentations, Phase 3 results for ELREXFIO in relapsed or refractory multiple myeloma, PADCEV combination regulatory activity in bladder cancer, VYNDAMAX patent litigation settlements, and shareholder meeting communications.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Pfizer Inc. (NYSE: PFE) has announced a quarterly cash dividend of $0.41 per share for the second quarter of 2023. This dividend will be payable on June 9, 2023, to shareholders recorded by the close of business on May 12, 2023. This marks the 338th consecutive quarterly dividend paid by the company, highlighting its long-standing commitment to returning value to its shareholders. Pfizer continues to focus on bringing innovative therapies to the market and maintaining a robust financial position.